1
|
Perepliotchikov Y, Ziv-Baran T, Hindiyeh M, Manor Y, Sofer D, Moran-Gilad J, Stephens L, Mendelson E, Weil M, Bassal R, Anis E, Singer SR, Kaliner E, Cooper G, Majumdar M, Markovich M, Ram D, Grotto I, Gamzu R, Martin J, Shulman LM. Inferring Numbers of Wild Poliovirus Excretors Using Quantitative Environmental Surveillance. Vaccines (Basel) 2021; 9:870. [PMID: 34451995 PMCID: PMC8402366 DOI: 10.3390/vaccines9080870] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2021] [Revised: 07/22/2021] [Accepted: 07/29/2021] [Indexed: 01/19/2023] Open
Abstract
Response to and monitoring of viral outbreaks can be efficiently focused when rapid, quantitative, kinetic information provides the location and the number of infected individuals. Environmental surveillance traditionally provides information on location of populations with contagious, infected individuals since infectious poliovirus is excreted whether infections are asymptomatic or symptomatic. Here, we describe development of rapid (1 week turnaround time, TAT), quantitative RT-PCR of poliovirus RNA extracted directly from concentrated environmental surveillance samples to infer the number of infected individuals excreting poliovirus. The quantitation method was validated using data from vaccination with bivalent oral polio vaccine (bOPV). The method was then applied to infer the weekly number of excreters in a large, sustained, asymptomatic outbreak of wild type 1 poliovirus in Israel (2013) in a population where >90% of the individuals received three doses of inactivated polio vaccine (IPV). Evidence-based intervention strategies were based on the short TAT for direct quantitative detection. Furthermore, a TAT shorter than the duration of poliovirus excretion allowed resampling of infected individuals. Finally, the method documented absence of infections after successful intervention of the asymptomatic outbreak. The methodologies described here can be applied to outbreaks of other excreted viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), where there are (1) significant numbers of asymptomatic infections; (2) long incubation times during which infectious virus is excreted; and (3) limited resources, facilities, and manpower that restrict the number of individuals who can be tested and re-tested.
Collapse
Affiliation(s)
- Yuri Perepliotchikov
- Central Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; (Y.P.); (M.H.); (Y.M.); (D.S.); (E.M.); (M.W.); (D.R.)
| | - Tomer Ziv-Baran
- School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel; (T.Z.-B.); (R.G.)
| | - Musa Hindiyeh
- Central Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; (Y.P.); (M.H.); (Y.M.); (D.S.); (E.M.); (M.W.); (D.R.)
- School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel; (T.Z.-B.); (R.G.)
| | - Yossi Manor
- Central Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; (Y.P.); (M.H.); (Y.M.); (D.S.); (E.M.); (M.W.); (D.R.)
| | - Danit Sofer
- Central Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; (Y.P.); (M.H.); (Y.M.); (D.S.); (E.M.); (M.W.); (D.R.)
| | - Jacob Moran-Gilad
- Public Health Services, MOH, Jerusalem 9101002, Israel; (J.M.-G.); (E.A.); (S.R.S.); (E.K.); (I.G.)
- Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 8410501, Israel
| | - Laura Stephens
- National Institute for Biological Standards and Controls, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK; (L.S.); (G.C.); (M.M.); (J.M.)
| | - Ella Mendelson
- Central Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; (Y.P.); (M.H.); (Y.M.); (D.S.); (E.M.); (M.W.); (D.R.)
- School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel; (T.Z.-B.); (R.G.)
| | - Merav Weil
- Central Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; (Y.P.); (M.H.); (Y.M.); (D.S.); (E.M.); (M.W.); (D.R.)
| | - Ravit Bassal
- Israel Center for Disease Control, Ministry of Health, Gertner Building, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; (R.B.); (M.M.)
| | - Emilia Anis
- Public Health Services, MOH, Jerusalem 9101002, Israel; (J.M.-G.); (E.A.); (S.R.S.); (E.K.); (I.G.)
- Braun School of Public Health and Community Medicine, Hebrew University Hadassah Faculty of Medicine, Ein Kerem. P.O. Box 12271, Jerusalem 9112102, Israel
| | - Shepherd Roee Singer
- Public Health Services, MOH, Jerusalem 9101002, Israel; (J.M.-G.); (E.A.); (S.R.S.); (E.K.); (I.G.)
- Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 8410501, Israel
| | - Ehud Kaliner
- Public Health Services, MOH, Jerusalem 9101002, Israel; (J.M.-G.); (E.A.); (S.R.S.); (E.K.); (I.G.)
| | - Gillian Cooper
- National Institute for Biological Standards and Controls, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK; (L.S.); (G.C.); (M.M.); (J.M.)
| | - Manasi Majumdar
- National Institute for Biological Standards and Controls, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK; (L.S.); (G.C.); (M.M.); (J.M.)
| | - Michal Markovich
- Israel Center for Disease Control, Ministry of Health, Gertner Building, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; (R.B.); (M.M.)
| | - Daniela Ram
- Central Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; (Y.P.); (M.H.); (Y.M.); (D.S.); (E.M.); (M.W.); (D.R.)
| | - Itamar Grotto
- Public Health Services, MOH, Jerusalem 9101002, Israel; (J.M.-G.); (E.A.); (S.R.S.); (E.K.); (I.G.)
- Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 8410501, Israel
| | - Ronni Gamzu
- School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel; (T.Z.-B.); (R.G.)
- Public Health Services, MOH, Jerusalem 9101002, Israel; (J.M.-G.); (E.A.); (S.R.S.); (E.K.); (I.G.)
| | - Javier Martin
- National Institute for Biological Standards and Controls, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK; (L.S.); (G.C.); (M.M.); (J.M.)
| | - Lester M. Shulman
- Central Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; (Y.P.); (M.H.); (Y.M.); (D.S.); (E.M.); (M.W.); (D.R.)
- School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel; (T.Z.-B.); (R.G.)
| |
Collapse
|
2
|
Shaghaghi M, Shahmahmoodi S, Abolhassani H, Soleyman-Jahi S, Parvaneh L, Mahmoudi S, Chavoshzadeh Z, Yazdani R, Zahraei SM, Ebrahimi M, Eslamian MH, Tabatabaie H, Yousefi M, Kandelousi YM, Oujaghlou A, Rezaei N, Aghamohammadi A. Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995-2014. Emerg Infect Dis 2018; 22:1712-9. [PMID: 27648512 PMCID: PMC5038407 DOI: 10.3201/eid2210.151071] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Polio might not be eradicated unless long-term vaccination with inactivated poliovirus vaccine is implemented. Widespread use of oral poliovirus vaccine has led to an ≈99.9% decrease in global incidence of poliomyelitis (from ≈350,000 cases in 1988 to 74 cases in 2015) and eradication of wild-type poliovirus serotypes 2 and 3. However, patients with primary immunodeficiency might shed vaccine-derived polioviruses (VDPVs) for an extended period, which could pose a major threat to polio eradication programs. Since 1995, sixteen VDPV populations have been isolated from 14 patients with immunodeficiency in Iran. For these patients, vaccine-associated paralysis, mostly in >1 extremity, was the first manifestation of primary immunodeficiency. Seven patients with humoral immunodeficiency cleared VDPV infection more frequently than did 6 patients with combined immunodeficiencies. Our results raise questions about manifestations of VDPVs in immunodeficient patients and the role of cellular immunity against enterovirus infections. On the basis of an association between VDPVs and immunodeficiency, we advocate screening of patients with primary immunodeficiency for shedding of polioviruses.
Collapse
|
3
|
Environmental surveillance of poliovirus in sewage water around the introduction period for inactivated polio vaccine in Japan. Appl Environ Microbiol 2015; 81:1859-64. [PMID: 25556189 DOI: 10.1128/aem.03575-14] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Environmental virus surveillance was conducted at two independent sewage plants from urban and rural areas in the northern prefecture of the Kyushu district, Japan, to trace polioviruses (PVs) within communities. Consequently, 83 PVs were isolated over a 34-month period from April 2010 to January 2013. The frequency of PV isolation at the urban plant was 1.5 times higher than that at the rural plant. Molecular sequence analysis of the viral VP1 gene identified all three serotypes among the PV isolates, with the most prevalent serotype being type 2 (46%). Nearly all poliovirus isolates exhibited more than one nucleotide mutation from the Sabin vaccine strains. During this study, inactivated poliovirus vaccine (IPV) was introduced for routine immunization on 1 September 2012, replacing the live oral poliovirus vaccine (OPV). Interestingly, the frequency of PV isolation from sewage waters declined before OPV cessation at both sites. Our study highlights the importance of environmental surveillance for the detection of the excretion of PVs from an OPV-immunized population in a highly sensitive manner, during the OPV-to-IPV transition period.
Collapse
|
7
|
Abstract
The six serotypes of the group B coxsackieviruses (CVB) are common human enteroviruses linked etiologically to inflammatory cardiomyopathies. This has been demonstrated by molecular detection of enteroviral RNA in human heart tissue, serologic associations with disease, and virus isolation from cases of fulminant myocarditis. The murine model of CVB-associated myocarditis has demonstrated that CVB can be attenuated through mutations at different genomic sites. Human CVB3 isolates demonstrate varying degrees of cardiovirulence in the murine model; one site of virulence determination has been mapped to domain II of the 5' non-translated region. The interplay of CVB replication and the immune response to that replication in the heart is a complex interaction determining the extent to which the virus replication is limited and the degree to which a pathogenic inflammation of cardiac muscle occurs. Studies of CVB3-induced myocarditis in murine strains lacking subsets of the immune system or genes regulating the immune response have demonstrated a pivotal role of the T cell response to the generation of myocarditis. While CVB are associated with 20-25% of cases of myocarditis or cardiomyopathy, the severity of the disease and the existence of attenuated strains shown to generate protective immunity in animal models indicates that vaccination against the CVBs would be valuable.
Collapse
Affiliation(s)
- K S Kim
- Enterovirus Research Laboratory, Department of Pathology and Microbiology, University of Nebraska Medical Center, 986495 Nebraska Medical Center, Omaha, NE 68198-6495, USA
| | | | | | | |
Collapse
|
8
|
Dodd DA, Giddings TH, Kirkegaard K. Poliovirus 3A protein limits interleukin-6 (IL-6), IL-8, and beta interferon secretion during viral infection. J Virol 2001; 75:8158-65. [PMID: 11483761 PMCID: PMC115060 DOI: 10.1128/jvi.75.17.8158-8165.2001] [Citation(s) in RCA: 132] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
During viral infections, the host secretory pathway is crucial for both innate and acquired immune responses. For example, the export of most proinflammatory and antiviral cytokines, which recruit lymphocytes and initiate antiviral defenses, requires traffic through the host secretory pathway. To investigate potential effects of the known inhibition of cellular protein secretion during poliovirus infection on pathogenesis, cytokine secretion from cells infected with wild-type virus and with 3A-2, a mutant virus carrying an insertion in viral protein 3A which renders the virus defective in the inhibition of protein secretion, was tested. We show here that cells infected with 3A-2 mutant virus secrete greater amounts of cytokines interleukin-6 (IL-6), IL-8, and beta interferon than cells infected with wild-type poliovirus. Increased cytokine secretion from the mutant-infected cells can be attributed to the reduced inhibition of host protein secretion, because no significant differences between 3A-2- and wild-type-infected cells were observed in the inhibition of viral growth, host cell translation, or the ability of wild-type- or 3A-2-infected cells to support the transcriptional induction of beta interferon mRNA. We surmise that the wild-type function of 3A in inhibiting ER-to-Golgi traffic is not required for viral replication in tissue culture but, by altering the amount of secreted cytokines, could have substantial effects on pathogenesis within an infected host. The global inhibition of protein secretion by poliovirus may reflect a general mechanism by which pathogens that do not require a functional protein secretory apparatus can reduce the native immune response and inflammation associated with infection.
Collapse
Affiliation(s)
- D A Dodd
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94309, USA
| | | | | |
Collapse
|